CN113616732A - Formula and preparation method of ginseng-olive tablet - Google Patents
Formula and preparation method of ginseng-olive tablet Download PDFInfo
- Publication number
- CN113616732A CN113616732A CN202111015571.9A CN202111015571A CN113616732A CN 113616732 A CN113616732 A CN 113616732A CN 202111015571 A CN202111015571 A CN 202111015571A CN 113616732 A CN113616732 A CN 113616732A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginseng
- olive
- drying
- material obtained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000009472 formulation Methods 0.000 title description 5
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 50
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 50
- 235000008434 ginseng Nutrition 0.000 claims abstract description 50
- 240000007817 Olea europaea Species 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 30
- 244000119298 Emblica officinalis Species 0.000 claims abstract description 17
- 235000015489 Emblica officinalis Nutrition 0.000 claims abstract description 17
- 240000000249 Morus alba Species 0.000 claims abstract description 14
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 14
- 241000756042 Polygonatum Species 0.000 claims abstract description 14
- 235000011034 Rubus glaucus Nutrition 0.000 claims abstract description 14
- 235000009122 Rubus idaeus Nutrition 0.000 claims abstract description 14
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 11
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 8
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 8
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 8
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 8
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims description 58
- 239000000463 material Substances 0.000 claims description 56
- 238000001035 drying Methods 0.000 claims description 53
- 239000000843 powder Substances 0.000 claims description 38
- 238000003756 stirring Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 235000013399 edible fruits Nutrition 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 240000007651 Rubus glaucus Species 0.000 claims description 12
- 238000009835 boiling Methods 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 7
- 244000241872 Lycium chinense Species 0.000 claims description 6
- 235000015468 Lycium chinense Nutrition 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 238000005507 spraying Methods 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 5
- 238000012216 screening Methods 0.000 claims description 5
- 239000003472 antidiabetic agent Substances 0.000 claims description 4
- 238000010298 pulverizing process Methods 0.000 claims description 4
- 235000004879 dioscorea Nutrition 0.000 claims description 3
- 239000011344 liquid material Substances 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 13
- 230000000694 effects Effects 0.000 abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 17
- 201000001421 hyperglycemia Diseases 0.000 abstract description 13
- 244000235659 Rubus idaeus Species 0.000 abstract description 2
- 230000036449 good health Effects 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 2
- 240000004371 Panax ginseng Species 0.000 description 35
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 230000007812 deficiency Effects 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 210000000952 spleen Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 9
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 206010011224 Cough Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 240000001972 Gardenia jasminoides Species 0.000 description 6
- 210000001124 body fluid Anatomy 0.000 description 6
- 239000010839 body fluid Substances 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 206010003549 asthenia Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000022531 anorexia Diseases 0.000 description 4
- 206010061428 decreased appetite Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 230000035922 thirst Effects 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 235000018958 Gardenia augusta Nutrition 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010041497 Spermatorrhoea Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000013403 hyperactivity Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 208000005946 Xerostomia Diseases 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 201000009361 ascariasis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000009609 fructus phyllanthi Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000244186 Ascaris Species 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000037319 Hepatitis infectious Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940127560 insulin pen Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses ginseng olive slices, which comprise ginseng, phyllanthus emblica, medlar, Chinese yam, rhizoma polygonati, mulberry, raspberry, dark plum, gardenia and polygonatum. The invention not only has good curative effect on hyperglycemia crowds, but also has good health care function on early-stage diabetes patients, and particularly has better curative effect on hyperglycemia crowds. It is another object of the invention to provide a process for the preparation of the product.
Description
Technical Field
The invention relates to the field of production and manufacturing of traditional Chinese medicine decoction pieces, and in particular relates to ginseng olive pieces and a preparation method thereof.
Background
It is known that long-term hyperglycemia causes pathological changes of various tissues and organs of the whole body, which lead to electrolyte disorder, nutrient deficiency, resistance reduction, renal function impairment, neuropathy, fundus oculi lesion, cardiovascular and cerebrovascular diseases and even death. Hyperglycemia is also a risk factor for inducing various cancers. May increase the risk of women suffering from breast cancer, endometrial cancer and ovarian cancer, and men suffering from colorectal cancer, bladder cancer and other diseases.
At present, western medicines for treating diabetes mainly comprise two main types of oral hypoglycemic chemical medicines and insulin. In terms of disease treatment, insulin can be said to be the main treatment means except oral medicine, and the injection matching of insulin and insulin pen is still the mainstream choice of diabetic patients. However, such treatments are prone to hypoglycemia, are life-threatening in severe cases, and also have allergic reactions when insulin is injected.
The ginseng olive tablet is prepared from a plurality of edible and medicinal food materials through scientific proportioning and modern technology, is convenient to eat, has a good blood sugar reducing effect on the early stage of hyperglycemia, is convenient to carry, does not have any toxic or side effect, and the like, and is increasingly selected by people with hyperglycemia.
Disclosure of Invention
The invention aims to provide ginseng olive tablets and a preparation method thereof, and aims to solve the problems in the prior art.
In order to solve the technical problems, the invention adopts the following technical scheme:
a Ginseng and fructus Canarii albi tablet comprises Ginseng radix, fructus Phyllanthi, fructus Lycii, rhizoma Dioscoreae, rhizoma Polygonati, Mori fructus, Rubi fructus, mume fructus, fructus Gardeniae, and rhizoma Polygonati Odorati.
Further, 22-30 parts of ginseng is included according to the mass ratio; 20-25 parts of emblic leafflower fruit, 10-15 parts of Chinese wolfberry, 10-15 parts of Chinese yam, 5-10 parts of rhizoma polygonati, 5-10 parts of mulberry, 5-10 parts of raspberry, 1-5 parts of dark plum, 1-5 parts of gardenia and 1-5 parts of polygonatum.
Further, the health care tea comprises 24 parts of ginseng, 22 parts of emblic leafflower fruit, 14 parts of Chinese wolfberry, 11 parts of Chinese yam, 8 parts of rhizoma polygonati, 7 parts of mulberry, 7 parts of raspberry, 3 parts of dark plum, 2 parts of cape jasmine and 2 parts of polygonatum.
Further, the preparation method of the ginseng olive tablet comprises the following steps:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials in proportion, pulverizing and bagging for later use;
s3, adding water into part of the dry powder raw material obtained in the step S2, and putting the raw material into an extraction tank for steam heating and boiling;
s4, conveying the liquid material decocted in the step S3 to a concentration tank through a pipeline for steam heating and concentration;
s5, outputting the concentrated material obtained in the step S4 to a jacketed kettle through a conveying pipeline for continuous boiling; stirring is continued until the mixture is cooked to be thick.
S6, transferring the material obtained in the step S5 into a stirring container, pouring the residual dry powder raw material obtained in the step S2 into the stirring container, stirring and mixing the materials together, and naturally cooling the materials in the stirring process;
s7, putting the material obtained in the step S6 into a baking tray, and drying for the first time;
s8, performing secondary powder grinding operation on the material processed in the step S7, and screening powder by using a 80-100-mesh sieve for later use;
s9, uniformly spraying 10% of white sugar water on the surface of the material obtained in the step S8 for later use;
s10, placing the material obtained in the step S9 into an oven for secondary drying, and taking out and granulating when the water content is reduced to 30-50%;
s11, putting the material obtained in the step S10 into an oven for drying for three times until the drying is complete;
and S12, tabletting the granules obtained in the step S11 and packaging.
Further, the mass of part of the dry powder raw material in the step S3 accounts for 92-96% of the total raw material mass; the mass of the residual dry powder raw material in the step S6 accounts for 4-8% of the total raw material mass
Further, the mass ratio of the dry powder raw material to the water in the step S3 is 1: 10.
Further, the vacuum concentration extraction temperature in step S4 is 150-165 ℃.
Further, the primary drying temperature is 70-80 ℃, and the drying time is 24-48 h; the secondary drying temperature is 70-90 ℃, and the drying time is 2-3 h; the third drying temperature is 80-100 ℃, and the drying time is 3-6 h.
The application method of the ginseng olive tablet comprises the step of preparing a hypoglycemic drug or health-care product.
The application of the ginseng olive tablet prepared by the method is that the ginseng olive tablet is used for preparing hypoglycemic drugs or health care products.
Ginseng: the recorded functions of the Chinese pharmacopoeia are mainly used for reinforcing primordial qi, recovering pulse, relieving depletion, tonifying spleen, benefiting lung, promoting fluid production and soothing the nerves. Can be used for treating asthenia, collapse, cold limbs, weak pulse, spleen deficiency, anorexia, lung deficiency, cough, asthma, body fluid deficiency, thirst, internal heat, asthenia, palpitation, insomnia, sexual impotence, and cold womb; heart failure, cardiogenic shock.
Emblic leafflower fruit: also called Yunnan olive. The recorded functions of the Chinese pharmacopoeia mainly include clearing heat and cooling blood, promoting digestion and strengthening stomach, and promoting the production of body fluid to relieve cough. Can be used for treating blood heat and blood stasis, dyspepsia, abdominal distention, cough, laryngalgia, and xerostomia.
Medlar: the recorded functions of the Chinese pharmacopoeia mainly are used for nourishing liver and kidney, replenishing vital essence and improving eyesight. Can be used for treating asthenia, soreness of waist and knees, vertigo, tinnitus, internal heat, diabetes, blood deficiency, sallow complexion, and blurred vision.
Chinese yam: the recorded functions of the Chinese pharmacopoeia are mainly used for tonifying spleen and nourishing stomach, promoting the production of body fluid and benefiting lung, and tonifying kidney and arresting seminal emission. Can be used for treating spleen deficiency, anorexia, chronic diarrhea, lung deficiency, cough, asthma, spermatorrhea, leukorrhagia, frequent micturition, and diabetes due to deficiency heat. The bran-parched rhizoma Dioscoreae has effects of invigorating spleen and invigorating stomach. Can be used for treating spleen deficiency, anorexia, diarrhea, loose stool, and leukorrhagia.
Rhizoma polygonati: the recorded functions of the Chinese pharmacopoeia mainly comprise tonifying qi and yin, strengthening spleen, moistening lung and tonifying kidney. Can be used for treating weakness of spleen and stomach, asthenia, xerostomia, anorexia, lung deficiency, cough, essence and blood deficiency, and internal heat diabetes.
And (3) mulberry fruit: the record of Chinese pharmacopoeia records that the functions of the Chinese pharmacopoeia mainly are enriching blood and nourishing yin, and promoting the production of body fluid and moistening dryness. Can be used for treating vertigo, tinnitus, palpitation, insomnia, premature gray hair, thirst due to body fluid consumption, internal heat, diabetes, and constipation due to blood deficiency.
Raspberry: the record in the Chinese pharmacopoeia has the main functions of tonifying kidney, securing essence and reducing urination. Can be used for treating enuresis due to kidney deficiency, frequent micturition, sexual impotence, premature ejaculation, spermatorrhea, and spermatorrhea.
Dark plum: the recorded functions of the Chinese pharmacopoeia are mainly used for astringing lung, astringing intestine, promoting fluid production and calming ascaris. Can be used for treating lung deficiency, chronic cough, chronic dysentery, intestine dryness, asthenia heat, diabetes, ascariasis, emesis, abdominal pain, and biliary ascariasis.
Gardenia: the Chinese pharmacopoeia records the main function:
fruit: purging fire, relieving restlessness, clearing heat, inducing diuresis, cooling blood and removing toxicity. Can be used for treating vexation due to fever, jaundice, dark urine, stranguria with blood, pain, hematemesis, epistaxis, conjunctival congestion, swelling and pain, and pyocutaneous disease due to pathogenic fire; it can be used for treating sprain, contusion and pain.
Root: purging fire and removing toxicity, clearing heat and promoting diuresis, cooling blood and dissipating blood stasis. Can be used for treating infectious hepatitis, traumatic injury, and toothache due to pathogenic wind-fire.
Fragrant solomonseal rhizome: to nourish yin, moisten dryness, promote the production of body fluid and quench thirst. Can be used for treating yin injury of lung and stomach, cough due to dryness-heat, dry throat, thirst, and diabetes due to internal heat.
The traditional Chinese medicine considers that the root cause of the generation and the development of the diabetes mellitus has direct relation with the obstructed veins and the imbalance of yin and yang of viscera caused by improper diet, emotional disorder, overstrain, internal injury, exogenous pathogenic toxin. The traditional Chinese medicine considers that people with the following constitutions are susceptible people to diabetes: people with stomach channel hyperactivity (stomach heat constitution) are easy to hungry and eat a lot; those with kidney channel deficiency (kidney deficiency) are prone to physical weakness and also to fatigue, most likely to develop diabetes; also, people with hyperactivity of liver meridian (hyperactivity of liver) are prone to develop spleen qi or are hypertensive; also for those with the constitution of gallbladder channel blockage (constitution of liver depression), such people always generate stuffy qi slowly, and are stuffy and uncomfortable for the old, and are also very easy to suffer from diabetes; also, people with spleen channel weakness have a poor digestive system and are prone to diabetes. These people are all those who have an imbalance of yin and yang in their zang-fu organs. For the above reasons, as a health-care functional tablet, the conditioning of body functions before the development of diabetes is emphasized, and unlike the conventional blood sugar lowering tablet, the short-term rapid blood sugar lowering component is not used for each component in the present application. Experiments prove that the main components of the ginseng and the emblic leafflower fruit are matched with each other, and the health care effect on reducing blood sugar is achieved after the ginseng and the emblic leafflower fruit are regularly taken for a long time by combining the preparation method, and meanwhile, the medlar, the yam, the sealwort, the mulberry, the raspberry, the dark plum, the gardenia and the polygonatum are matched, so that the side effects of the ginseng and the emblic leafflower fruit on the body are regulated, the health care effect is enhanced, and a certain help effect is achieved on tabletting.
Compared with the prior art, the invention has at least one of the following beneficial effects:
1. the ginseng olive tablet provided by the invention has the advantages that the main components of the ginseng olive tablet are ginseng and emblic leafflower fruit, and meanwhile, various pure natural medicinal and edible components are added, so that the effect of reducing blood sugar is achieved according to a scientific proportion.
2. The invention not only has good curative effect on hyperglycemia crowds, but also has good health care function on early-stage diabetes patients, and particularly has better curative effect on hyperglycemia crowds. It is another object of the invention to provide a process for the preparation of the product.
3. The invention discloses a novel medicine-food homologous product for regulating hyperglycemia, which is prepared by adopting roots, stems, leaves, flowers, fruits and seeds of various pure natural medicine-food homologous foods, crushing, extracting, concentrating, drying, secondarily crushing, sieving by using a sieve with 80-120 meshes, granulating, tabletting and packaging by uniformly spraying white sugar water.
4. The ginseng olive tablet is refined from various medicinal and edible food materials, and has a good health-care function on hyperglycemia, diabetic early-stage crowds and the like.
5. The active components of the invention are all medicinal and edible, no other additive components are contained, and the tabletting is not added with conventional adhesives, so that the good morphological structure can be ensured, and the drug dissolution effect can be ensured.
6. According to the preparation method of the ginseng olive tablet, the effective ingredients in the components are fully extracted through multiple times of boiling and concentration, the medium effects of granulation and tabletting are realized through the white sugar water, the viscosity is improved, the granulation is easier, and meanwhile, the drug properties are harmonized; the application also adopts a preparation method of mixing the raw medicinal powder and the extract in proportion, so that the effective components in the tablet are more specifically directed to control blood sugar, and the tablet is more favorable for tabletting and forming compared with the conventional extraction.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention is further described in detail with reference to the following embodiments. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
Example 1:
a Ginseng and fructus Canarii albi tablet comprises Ginseng radix, fructus Phyllanthi, fructus Lycii, rhizoma Dioscoreae, rhizoma Polygonati, Mori fructus, Rubi fructus, mume fructus, fructus Gardeniae, and rhizoma Polygonati Odorati.
Example 2:
on the basis of example 1:
comprises 22 to 30 portions of ginseng; 20-25 parts of emblic leafflower fruit, 10-15 parts of Chinese wolfberry, 10-15 parts of Chinese yam, 5-10 parts of rhizoma polygonati, 5-10 parts of mulberry, 5-10 parts of raspberry, 1-5 parts of dark plum, 1-5 parts of gardenia and 1-5 parts of polygonatum.
Example 3:
on the basis of examples 1-2:
comprises 24 parts of ginseng, 22 parts of emblic leafflower fruit, 14 parts of medlar, 11 parts of yam, 8 parts of rhizoma polygonati, 7 parts of mulberry, 7 parts of raspberry, 3 parts of dark plum, 2 parts of gardenia and 2 parts of polygonatum by mass ratio.
Example 4:
on the basis of examples 1 to 3:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials in proportion, pulverizing and bagging for later use;
s3, adding water into part of the dry powder raw material obtained in the step S2, and putting the raw material into an extraction tank for steam heating and boiling;
s4, conveying the liquid material decocted in the step S3 into a concentration tank through a pipeline for steam heating concentration;
s5, outputting the concentrated material obtained in the step S4 to a jacketed kettle through a conveying pipeline for continuous boiling; stirring is continued until the mixture is cooked to be thick.
S6, transferring the material obtained in the step S5 into a stirring container, pouring the residual dry powder raw material obtained in the step S2 into the stirring container, stirring and mixing the materials together, and naturally cooling the materials in the stirring process;
s7, putting the material obtained in the step S6 into a baking tray, and drying for the first time;
s8, performing secondary powder grinding operation on the material processed in the step S7, and screening powder by using a 80-100-mesh sieve for later use;
s9, uniformly spraying 10% of white sugar water on the surface of the material obtained in the step S8 for later use;
s10, placing the material obtained in the step S9 into an oven for secondary drying, and taking out and granulating when the water content is reduced to 30-50%;
s11, putting the material obtained in the step S10 into an oven for drying for three times until the drying is complete;
and S12, tabletting the granules obtained in the step S11 and packaging.
Example 5:
on the basis of examples 1 to 4:
the mass of part of the dry powder raw materials in the step S3 accounts for 92-96% of the total raw materials; the mass of the residual dry powder raw material in the step S6 accounts for 4-8% of the total raw material mass.
Example 6:
on the basis of examples 1 to 5:
the mass ratio of the dry powder raw material to the water in the step S3 is 1: 10.
Example 7:
on the basis of examples 1 to 6: the extraction temperature in step S4 was 150-165 ℃ in vacuum concentration.
Example 8:
on the basis of examples 1 to 7: the primary drying temperature is 70-80 ℃, and the drying time is 24-48 h; the secondary drying temperature is 70-90 ℃, and the drying time is 2-3 h; the third drying temperature is 80-100 ℃, and the drying time is 3-6 h.
Example 9:
a formula of ginseng olive tablet comprises the following components:
the traditional Chinese medicine composition comprises, by mass, 22 parts of ginseng, 20 parts of emblic leafflower fruit, 15 parts of Chinese wolfberry, 15 parts of Chinese yam, 5 parts of rhizoma polygonati, 10 parts of mulberry, 10 parts of raspberry, 1 part of dark plum, 5 parts of cape jasmine and 5 parts of polygonatum.
Example 10:
a formula of ginseng olive tablet comprises the following components:
according to the mass ratio, 30 parts of ginseng, 25 parts of emblic leafflower fruit, 10 parts of medlar, 10 parts of Chinese yam, 10 parts of rhizoma polygonati, 5 parts of mulberry, 5 parts of raspberry, 5 parts of dark plum, 1 part of gardenia and 1 part of polygonatum.
Example 11:
a formula of ginseng olive tablet comprises the following components:
according to the mass ratio, 23 parts of ginseng, 23 parts of emblic leafflower fruit, 12 parts of medlar, 12 parts of Chinese yam, 10 parts of rhizoma polygonati, 5 parts of mulberry, 6 parts of raspberry, 3 parts of dark plum, 3 parts of gardenia and 2 parts of polygonatum.
Example 12:
preferably, the formula of the ginseng olive tablet comprises the following components in parts by weight:
according to the mass ratio, the traditional Chinese medicine composition comprises 24 parts of ginseng, 22 parts of emblic leafflower fruit, 14 parts of Chinese wolfberry, 11 parts of Chinese yam, 8 parts of rhizoma polygonati, 7 parts of mulberry, 7 parts of raspberry, 3 parts of dark plum, 2 parts of cape jasmine and 2 parts of polygonatum.
Example 13:
preparation of ginseng olive tablet using the formulation of example 12 preparation method:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials according to the proportion of the embodiment 12, and then powdering and bagging the mixture for later use;
s3, taking 92% of the dry powder raw material obtained in the step S2, and putting the raw material into an extraction tank for high-temperature steam boiling according to the mass ratio of the dry powder raw material to water of 1: 10; in the process of boiling, 5-6L of water is added every 3-4h, and the total amount is added for 4-6 times, so that the nutrient substances are fully boiled out.
S4, conveying the boiled materials to an extraction tank through a pipeline for high-temperature steam concentration; the high-temperature vacuum concentration temperature is 160 ℃; in the concentration process, when the total amount of the concentrated liquid is about one half of the original liquid, the material is moved into a small-size extraction tank to be continuously concentrated so as to ensure the concentration effect.
S5, outputting the extracted materials to a jacketed kettle through a conveying pipeline for continuous boiling; stirring is continued until the mixture is cooked to be thick.
S6, transferring the material obtained in the step S5 into a stirring container, pouring the residual dry powder raw material obtained in the step S2 into the stirring container, stirring and mixing the materials together, and naturally cooling the materials in the stirring process;
s7, putting the material obtained in the step S6 into a baking tray, and drying for the first time; the primary drying temperature is 75 ℃, and the drying time is 24 h.
S8, performing secondary powder grinding operation on the material processed in the step S7, and screening powder by using a 80-100-mesh sieve for later use;
s9, uniformly spraying 10% of white sugar water on the surface of the material obtained in the step S8 for later use; the amount of sugar is controlled in the mass ratio of the dry powder raw material to the sugar of 20: 1. The sugar is used as an additive for auxiliary granulation of the binder, is safe and nontoxic on one hand, and is used for neutralizing drug properties on the other hand.
S10, placing the material obtained in the step S9 into an oven for secondary drying, and taking out and granulating when the water content is reduced to 30-50%; the secondary drying temperature is 85 ℃, and the drying time is 2-3 h.
S11, putting the material obtained in the step S10 into an oven for drying for three times until the drying is complete; the third drying temperature is 90-100 ℃.
And S12, tabletting the granules obtained in the step S11 and packaging.
The method adopts two crushing steps, wherein one crushing step is primary crushing after the raw materials are dried in the sun, so that the extraction of effective components is facilitated; the second time of crushing is to perform scattering and crushing operation on the half-dried material after the material is extracted and dried, so that subsequent granulation and tabletting are facilitated, and the uniformity of the material is further improved;
the method adopts three drying steps, wherein the first step is to extract raw materials, bake the raw materials and perform preliminary dehydration; the second drying is to dry and attach the white sugar water on the surface of the material, and further dehydrate to reach the water ratio required by granulation; the third drying step is to achieve the desired moisture content for tableting after granulation.
The method adopts two powder mixing steps, wherein solid and liquid are mixed for the first time to dissolve out the effective components; and the residual powder is added for the second time, so that the viscosity of the mixture can be adjusted, nutrient components which are not extracted and distributed are reserved, and the product effect is improved by combining the two. The proportion of the mixed powder is comprehensively selected according to the drug property and tabletting.
Example 14:
preparation of ginseng olive tablet using the formulation of example 12 preparation method:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials according to the proportion of the embodiment 12, and then powdering and bagging the mixture for later use;
s3, taking 96% of the dry powder raw material obtained in the step S2, and putting the raw material and water into an extraction tank according to the mass ratio of 1:10, and heating and decocting with steam; in the process of boiling, 5-6L of water is added every 3-4h, and the total amount is added for 4-6 times, so that the nutrient substances are fully boiled out.
S4, conveying the boiled materials to an extraction tank through a pipeline for steam heating concentration extraction; steam heating and concentrating at 165 deg.C; in the concentration process, when the total amount of the concentrated liquid is about one half of the original liquid, the material is transferred into a small-size concentration tank for continuous concentration so as to ensure the concentration effect.
S5, outputting the extracted materials to a jacketed kettle through a conveying pipeline for continuous boiling; stirring is continued until the mixture is cooked to be thick.
S6, transferring the material obtained in the step S5 into a stirring container, pouring the residual dry powder raw material obtained in the step S2 into the stirring container, stirring and mixing the materials together, and naturally cooling the materials in the stirring process;
s7, putting the material obtained in the step S6 into a baking tray, and drying for the first time; the primary drying temperature is 80 ℃, and the drying time is 30 hours;
s8, performing secondary powder grinding operation on the material processed in the step S7, and screening powder by using a 80-100-mesh sieve for later use;
s9, uniformly spraying 10% of white sugar water on the surface of the material obtained in the step S8 for later use; the amount of sugar is controlled in such a way that the mass ratio of the dry powder raw material to the sugar is 30: 1.
S10, placing the material obtained in the step S9 into an oven for secondary drying, and taking out and granulating when the water content is reduced to 30-50%; the drying temperature is 90 ℃, and the drying time is 2 hours;
s11, putting the material obtained in the step S10 into an oven for drying for three times until the drying is complete; the drying temperature is 95 ℃ and the drying time is 3 h.
And S12, tabletting the granules obtained in the step S11 and packaging.
Example 15:
a method of making ginseng olive tablet using the formulation of example 13:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials in proportion, pulverizing and bagging for later use;
and S3, directly tabletting the powder.
Test example:
50 middle-aged populations aged 40-60 years were selected and randomized into two groups of 25 subjects each. The selected subjects had a history of hyperglycemia.
The first group of subjects took 2 tablets per day (one tablet in the morning and one tablet each in the evening) prepared according to example 13;
the first group of subjects took 2 tablets per day (one each in the morning and evening) prepared according to example 15;
the results of testing blood glucose after 6 months are given in the following table:
table 1: example 15 blood glucose conditions
In conclusion, the decoction pieces prepared in the embodiment are taken by a group with symptoms of blood sugar increase or a history of blood sugar increase according to the dosage on time, and the blood sugar regulation effect is not obvious. For each raw material, the difference of the drug properties of the raw powder after direct tabletting and steaming extraction is large, the scientific proportion of raw clinker and extracted materials of each raw material weakens the drug properties of each raw material except blood sugar regulation, pertinently improves the blood sugar regulation and control capability of each raw material, and the raw powder has homology of medicine and food and has no other side effects.
Example 16:
test example:
100 middle-aged populations aged 40-60 years were selected and randomly divided into two groups of 50 subjects each. The selected subjects had a history of hyperglycemia.
The first group of subjects took 2 tablets per day (one tablet in the morning and one tablet each in the evening) prepared according to example 13;
the second group of subjects lived normally.
The results of testing blood glucose after 6 months are shown in table 2 below:
table 2: example 16 blood glucose conditions
The test example can prove that for the group with hyperglycemia symptom, the incidence rate can be reduced by taking the product in a small amount for a long time.
In conclusion, the decoction pieces disclosed by the application are taken by a group with symptoms of blood sugar increase or a history of blood sugar increase according to the dosage on time, so that the effect of maintaining the blood sugar stability is obvious.
Reference throughout this specification to "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment described generally in this application. The appearances of the same phrase in various places in the specification are not necessarily all referring to the same embodiment. Further, when a particular feature, structure, or characteristic is described in connection with any embodiment, it is submitted that it is within the scope of the invention to effect such feature, structure, or characteristic in connection with other embodiments.
Although the invention has been described herein with reference to a number of illustrative embodiments thereof, it should be understood that numerous other modifications and embodiments can be devised by those skilled in the art that will fall within the spirit and scope of the principles of this disclosure. More specifically, various variations and modifications are possible in the component parts and/or arrangements of the subject combination arrangement within the scope of the present description and claims. In addition to variations and modifications in the component parts and/or arrangements, other uses will also be apparent to those skilled in the art.
Claims (10)
1. A ginseng olive tablet is characterized by comprising ginseng, phyllanthus emblica, medlar, Chinese yam, rhizoma polygonati, mulberry, raspberry, dark plum, gardenia and polygonatum.
2. The ginseng olive tablet according to claim 1, wherein: 22-30 parts of ginseng according to the mass ratio; 20-25 parts of emblic leafflower fruit, 10-15 parts of Chinese wolfberry, 10-15 parts of Chinese yam, 5-10 parts of rhizoma polygonati, 5-10 parts of mulberry, 5-10 parts of raspberry, 1-5 parts of dark plum, 1-5 parts of gardenia and 1-5 parts of polygonatum.
3. The ginseng olive tablet according to claim 1, wherein: comprises 24 parts of ginseng, 22 parts of emblic leafflower fruit, 14 parts of medlar, 11 parts of yam, 8 parts of rhizoma polygonati, 7 parts of mulberry, 7 parts of raspberry, 3 parts of dark plum, 2 parts of gardenia and 2 parts of polygonatum by mass ratio.
4. A preparation method of ginseng olive slices is characterized by comprising the following steps: the method comprises the following steps:
s1, taking all raw materials, and airing the raw materials in a natural airing state for later use;
s2, mixing the dried raw materials in proportion, pulverizing and bagging for later use;
s3, adding water into part of the dry powder raw material obtained in the step S2, and putting the raw material into an extraction tank for steam heating and boiling;
s4, conveying the liquid material decocted in the step S3 into a concentration tank through a pipeline for steam heating concentration;
s5, outputting the concentrated material obtained in the step S4 to a jacketed kettle through a conveying pipeline for continuous boiling; stirring is continued until the mixture is cooked to be thick.
S6, transferring the material obtained in the step S5 into a stirring container, pouring the residual dry powder raw material obtained in the step S2 into the stirring container, stirring and mixing the materials together, and naturally cooling the materials in the stirring process;
s7, putting the material obtained in the step S6 into a baking tray, and drying for the first time;
s8, performing secondary powder grinding operation on the material processed in the step S7, and screening powder by using a 80-100-mesh sieve for later use;
s9, uniformly spraying 10% of white sugar water on the surface of the material obtained in the step S8 for later use;
s10, placing the material obtained in the step S9 into an oven for secondary drying, and taking out and granulating when the water content is reduced to 30-50%;
s11, putting the material obtained in the step S10 into an oven for drying for three times until the drying is complete;
and S12, tabletting the granules obtained in the step S11 and packaging.
5. The method for making ginseng olive slices according to claim 4, wherein the method comprises the following steps: the mass of part of the dry powder raw materials in the step S3 accounts for 92-96% of the total raw materials; the mass of the residual dry powder raw material in the step S6 accounts for 4-8% of the total raw material mass.
6. The method for making ginseng olive slices according to claim 4, wherein the method comprises the following steps: the mass ratio of the dry powder raw material to the water in the step S3 is 1: 10.
7. The method for making ginseng olive slices according to claim 4, wherein the method comprises the following steps: the extraction temperature in step S4 was 150-165 ℃ in vacuum concentration.
8. The method for making ginseng olive slices according to claim 4, wherein the method comprises the following steps: the primary drying temperature is 70-80 ℃, and the drying time is 24-48 h; the secondary drying temperature is 70-90 ℃, and the drying time is 2-3 h; the third drying temperature is 80-100 ℃, and the drying time is 3-6 h.
9. The method for using ginseng olive tablet according to claim 1, 2 or 3, wherein the method is used for manufacturing hypoglycemic drugs or health products.
10. The method for preparing ginseng olive tablet according to the method of claim 4, 5, 6, 7 or 8, wherein the method is used for preparing hypoglycemic drugs or health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111015571.9A CN113616732A (en) | 2021-08-31 | 2021-08-31 | Formula and preparation method of ginseng-olive tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111015571.9A CN113616732A (en) | 2021-08-31 | 2021-08-31 | Formula and preparation method of ginseng-olive tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113616732A true CN113616732A (en) | 2021-11-09 |
Family
ID=78388625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111015571.9A Pending CN113616732A (en) | 2021-08-31 | 2021-08-31 | Formula and preparation method of ginseng-olive tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113616732A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706707A (en) * | 2013-12-12 | 2015-06-17 | 余邦 | Antiviral immunity-enhancing ginseng healthcare product |
| CN105233119A (en) * | 2015-09-22 | 2016-01-13 | 张士舜 | Traditional Chinese medicine composition enhancing body immunity of middle-aged and aged people and preparation method thereof |
-
2021
- 2021-08-31 CN CN202111015571.9A patent/CN113616732A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104706707A (en) * | 2013-12-12 | 2015-06-17 | 余邦 | Antiviral immunity-enhancing ginseng healthcare product |
| CN105233119A (en) * | 2015-09-22 | 2016-01-13 | 张士舜 | Traditional Chinese medicine composition enhancing body immunity of middle-aged and aged people and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103734424B (en) | A kind of bitter buckwheat Weight-reducing and lipid-lowering constipation-relieving tea and preparation method thereof | |
| CN104873763A (en) | Health-care product for conditioning Qi deficiency constitution | |
| CN101467582B (en) | Refined lift-lengthening tea | |
| CN102755596B (en) | Traditional Chinese medicine for treating phlegm-dampness hyperplasia of mammary glands and preparation method thereof | |
| CN105920514A (en) | Traditional Chinese medicinal composition for treating metabolic syndrome | |
| CN103736036A (en) | Drug for treating nonalcoholic fatty liver disease and preparation method thereof | |
| CN103749818B (en) | A kind of sealwort hypoglycemic health protection tea and preparation method thereof | |
| CN106492084A (en) | A kind of pure draft traditional Chinese medicine capable of reducing weight product and preparation method thereof | |
| CN103719495A (en) | Great burdock achene healthcare tea for reducing blood glucose and lipid and preparation method thereof | |
| CN103285319B (en) | Chinese medicine composition for Polycystic Ovary Syndrome in Adolescence | |
| CN104856036B (en) | Health care medicated diet for treating iron-deficiency anemia and preparation method of health care medicated diet | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN105194295A (en) | Medicine composition for treating diabetes | |
| CN115120684B (en) | Chinese medicinal composition for treating diabetes and its preparation method | |
| CN113616732A (en) | Formula and preparation method of ginseng-olive tablet | |
| CN114344421A (en) | Medicinal and edible pure Chinese herbal medicine composition for treating hypertension and preparation method thereof | |
| CN105995542A (en) | Nutritional health-care black rice and strawberry crisp slices | |
| CN111567735A (en) | Noodle formula for regulating blood sugar and blood fat and improving physique | |
| CN104840629A (en) | Drug composition for treating cat jaundice and preparation method thereof | |
| CN114796417B (en) | Blood sugar reducing traditional Chinese medicine formula and preparation method thereof | |
| CN103989938A (en) | Chitosan composition for preventing and treating diabetes and preparation method of chitosan composition | |
| CN114712470B (en) | Medicine for treating deficiency of kidney of men and preparation method thereof | |
| CN107875288A (en) | Preparation method with promoting blood circulation, the Chinese medicine composition of beauty functions and its granule | |
| CN103099886A (en) | Soft capsule helpful for improving intestinal and gastric functions and preparation method thereof | |
| CN106578959A (en) | Food suitable for diabetic patients and production technology of food |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211109 |